- Home
- TPST vs ATCX Comparison
TPST vs ATCX Comparison
Compare TPST & ATCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TPST | ATCX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.2M |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TPST | ATCX |
|---|---|---|
| Price | $0.51 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.58 |
| AVG Volume (30 Days) | ★ 281.5K | 28.8K |
| Earning Date | 11-04-2026 | 03-16-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | $873.07 |
| Revenue Next Year | N/A | $122.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $2.02 |
| 52 Week High | $11.13 | $14.01 |
Technical Indicators
Market Signals| Indicator | TPST | ATCX |
|---|---|---|
| Relative Strength Index (RSI) | 27.11 | 33.98 |
| Support Level | N/A | N/A |
| Resistance Level | $1.24 | $3.26 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.12 | 16.87 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
About ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.